BrAD-R13

Last updated

BrAD-R13
Clinical data
Other namesBrADR13; Braegen-01; Braegen01
Routes of
administration 		Oral [1]
Drug class TrkB agonist

BrAD-R13, also known as Braegen-01, is a small-molecule tropomyosin receptor kinase B (TrkB) agonist which is under development for the treatment of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), depressive disorders, Parkinson's disease, and schizophrenia. [1] [2] [3] [4] It is taken orally. [1] The drug is a derivative of 7,8-dihydroxyflavone (7,8-DHF; tropoflavin). [3] [4] It was first described in the scientific literature by 2020. [3] BrAD-R13 is being developed by Braegen Pharmaceutical in China. [1] [2] As of August 2025, it is in phase 1 clinical trials for Alzheimer's disease and the preclinical research stage of development for all other indications. [1] [2] The exact chemical structure of BrAD-R13 does not yet appear to have been disclosed. [1]

See also

References

  1. 1 2 3 4 5 6 "BrAD R13". AdisInsight. 8 August 2025. Retrieved 24 January 2026.
  2. 1 2 3 "Delving into the Latest Updates on BrAD-R13 with Synapse". Synapse. 20 December 2025. Retrieved 24 January 2026.
  3. 1 2 3 Liu W, Wang X, O'Connor M, Wang G, Han F (2020). "Brain-Derived Neurotrophic Factor and Its Potential Therapeutic Role in Stroke Comorbidities". Neural Plasticity. 2020 1969482. doi: 10.1155/2020/1969482 . PMC   7204205 . PMID   32399020. Recently, a derivative of 7,8-DHF, namely, BrAD-R13, was approved by the FDA for use in clinical trials for the treatment of mild to moderate AD.
  4. 1 2 Wang D, Lang ZC, Wei SN, Wang W, Zhang H (June 2024). "Targeting brain-derived neurotrophic factor in the treatment of neurodegenerative diseases: A review". Neuroprotection. 2 (2): 67–78. doi:10.1002/nep3.43. PMC   12486910 . PMID   41383700. BrAD‐R13, a derivative of 7,8‐ DHF, has been approved by the FDA for clinical trials in mild to moderate disease, with preclinical studies supporting its efficacy against AD and ALS.18,134–136 Recently, BrAD‐R13 has been registered for a Phase I trial in China (CTR20233658).
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.